Tirzepatide 5 mg / 10 mg Vial

Description

Badges:

• HPLC/MS Verified
• Independent COA QR-linked
• Secure Payments (Card + Crypto)
• Fast Canadian Shipping

Science & Mechanism

Tirzepatide is a first-in-class dual agonist of GLP-1 and GIP receptors, amplifying satiety signaling, reducing energy intake, and improving insulin sensitivity. This dual-pathway design produces greater weight loss than semaglutide alone.

Evidence:

• SURMOUNT-1 trial: up to ~20.9% mean loss at 72 weeks; 57% of participants lost ≥20% of body weight.
• Consistently outperforms semaglutide in head-to-head comparisons.

Reconstitution & Dosing Tables (Weight Loss Peptides)

Tirzepatide (10 mg vial + 2 mL BAC water)

• Final concentration = 5 mg/mL → 50 mcg per unit (0.01 mL).

Dosing Guide (Educational)

Weekly SubQ Titration (SURMOUNT-1 protocol):

• Escalate every 4 weeks if tolerated.
• Maintenance most commonly at 10–15 mg weekly.

Reconstitution (10 mg vial example)

• Add 2 mL BAC water → concentration = 1 mg per 0.2 mL
• 2.5 mg dose = 0.5 mL (50 units)
• 10 mg dose = 2.0 mL (200 units)

Storage

• Store lyophilized vials refrigerated (2–8 °C).
• After reconstitution, refrigerate and use within 30 days.

Disclaimer

Educational information only. Not approved by Health Canada or FDA for lifestyle use. Customers assume responsibility for safe and informed handling.

FAQ

• How does it compare to Semaglutide?
  Trials show greater mean and % body weight loss with tirzepatide vs semaglutide.
• What’s the best stack?
  Most evidence supports solo use; however, MOTS-c may be added for mitochondrial energy support (exploratory).
• How long until results?
  Meaningful appetite suppression is often reported within the first 4–8 weeks; maximal weight loss occurs over 9–18 months.

📚 Tirzepatide – References & Product Page Citations

🔗 Direct References (Medical Papers & Sources)

1. SURMOUNT-1 Trial (PubMed abstract) — Landmark Phase 3 RCT
   https://pubmed.ncbi.nlm.nih.gov/35658024/
2. Wikipedia Overview (includes trial data)
   https://en.wikipedia.org/wiki/Tirzepatide
3. ADA Press Release — Up to 22.5% body weight loss
   https://diabetes.org/newsroom/surmount-1-study-finds-individuals-%2520with-obesity-lost-up-to-22.5-percent-body-weight-taking-tirzepatide
4. NEJM Head-to-Head Tirzepatide vs. Semaglutide (2025)
   https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
5. JWatch Summary — Head-to-head comparison
   https://www.jwatch.org/na58789/2025/05/15/tirzepatide-vs-semaglutide-patients-with-obesity-head-head
6. Lilly Investor Release — SURMOUNT-1 details
   https://investor.lilly.com/node/51651/pdf
7. Mechanism Review — Dual GLP-1/GIP agonism (PubMed)
   https://pubmed.ncbi.nlm.nih.gov/36050763/
8. TIME Health — How Mounjaro works for weight loss
   https://time.com/6284941/mounjaro-weight-loss/
9. Guardian — 3-Year Follow-Up, Sustained 23% Weight Loss
   https://www.theguardian.com/society/2025/apr/11/people-using-drug-mounjaro-sustain-weight-loss-over-three-years-trial-finds
10. Reuters — 94% Diabetes Risk Reduction
    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-says-weight-loss-drug-cut-diabetes-risk-by-94-trial-2024-08-20/
11. NCBI Bookshelf Clinical Overview
    https://www.ncbi.nlm.nih.gov/books/NBK585056/
12. Frontiers in Endocrinology Review — Tirzepatide as first-in-class dual agonist
    https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431292/full

✅ Suggested Product Page Citations

• Mean weight loss up to 20.9% at 72 weeks (15 mg dose, SURMOUNT-1). PubMed, Wikipedia
• ≥20% body weight reduction achieved by over half of participants at high doses. PubMed
• Head-to-head RCTs confirm tirzepatide outperforms semaglutide in weight and waist reduction. NEJM, JWatch
• Long-term efficacy: Sustained 23% mean weight loss at ~22 months, minimal rebound. Guardian
• Metabolic benefit: Reduced Type 2 diabetes risk by 94% in pre-diabetic individuals. Reuters
• Mechanism: Dual GIP + GLP-1 receptor agonism enhances satiety and insulin sensitivity, producing superior results vs single agonists. PubMed, Frontiers